Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cervarix post-marketing safety study in Chinese females
CTR20210523Phase 4Completed
- Sponsor
- GSK
- Start
- Mar 2021
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of human papillomavirus type 16 L1 capsid protein antigen in Cervical Cancer (CC), cervical intraepithelial neoplasia (CIN), cervical adenocarcinoma, sponsored by GSK. Started Mar 2021; status: completed.
02
Drugs
human papillomavirus type 16 L1 capsid protein antigen
03
Conditions
Cervical Cancer (CC)cervical intraepithelial neoplasia (CIN)cervical adenocarcinoma
Beyond the preview
Go deeper on CTR20210523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210523.